Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB-400 for Facial Redness and Bumps in Rosacea
NCT04508205Phase 1Completed
- Sponsor
- CAGE Bio
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of choline geranate in rosacea, sponsored by CAGE Bio. Primary endpoints: Investigator's Global Assessment at 12 weeks and Investigator's Global Assessment of Redness at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
choline geranate
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT04508205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508205.